Erudio Healtherudio.com
Clinical trial · no report yet · Phase 2
NCT05012371 trial: what clinicians have said so far
Lenvatinib With Everolimus Versus Cabozantinib for Second-Line or Third-Line Treatment of Metastatic Renal Cell Cancer
- NCT05012371 ↗
- Active, not recruiting
- M.D. Anderson Cancer Center
- Focused size, estimated: 1–150 verified statements once built
We haven't built an HCP commentary report on NCT05012371 (lenvatinib plus everolimus in metastatic clear cell renal cell carcinoma) yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Indexed commentary on NCT05012371 so far
Podcasts, YouTube videos and X posts we have indexed that name the trial. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.
| Indexed so far | |
|---|---|
| 3 YouTube videos, typically up to 13 once built | |
| 1 post on X, typically up to 4 once built |
The trial
ClinicalTrials.gov- Official title
- A Phase II Study of Lenvatinib Plus Everolimus Versus Cabozantinib in Patients With Metastatic Renal Cell Carcinoma That Progressed on A PD-1/PD-L1 Checkpoint Inhibitor
- Phase
- Phase 2
- Status
- Active, not recruiting
- Conditions
- Advanced Clear Cell Renal Cell Carcinoma; Metastatic Clear Cell Renal Cell Carcinoma; Stage III Renal Cell Cancer AJCC v8; Stage IV Renal Cell Cancer AJCC v8
- Interventions
- Cabozantinib; Everolimus; Lenvatinib; Questionnaire Administration
- Arms
- Arm A (lenvatinib, everolimus) · Experimental
- Arm B (cabozantinib) · Active comparator
- Enrollment
- 90
- Primary outcomes
- Progression-Free Survival (PFS)
- Sponsor
- M.D. Anderson Cancer Center with National Cancer Institute (NCI)
- Start
- Feb 16, 2022
- Primary completion
- Oct 25, 2027 (estimated)
- Results posted
- No
- Registry record
- NCT05012371 · updated Sep 14, 2026